# Effects of Empagliflozin-Metformin, Sitagliptin-Metformin, and Metformin on Adipokines in Type 2 Diabetes

Study · id `cardio:ct-nct07531108` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07531108](<https://clinicaltrials.gov/study/NCT07531108>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07531108

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 186 participants.

## Technical summary

Registry record NCT07531108. Non-randomized; no masking; primary purpose treatment. Start 2024-11-15 (actual); primary completion 2025-11-27 (actual). Results not posted.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 186 participants (enrolled count; ClinicalTrials.gov record NCT07531108, source copy `cardio:ctgov-nct07531108-2026-04-15`, retrieved 2026-10-26)
- Started: 2024-11-15 (actual) (ClinicalTrials.gov record NCT07531108, source copy `cardio:ctgov-nct07531108-2026-04-15`, retrieved 2026-10-26)
- Primary completion: 2025-11-27 (actual) (ClinicalTrials.gov record NCT07531108, source copy `cardio:ctgov-nct07531108-2026-04-15`, retrieved 2026-10-26)
- Completion: 2025-11-27 (actual) (ClinicalTrials.gov record NCT07531108, source copy `cardio:ctgov-nct07531108-2026-04-15`, retrieved 2026-10-26)
- Countries: Iraq (ClinicalTrials.gov record NCT07531108, source copy `cardio:ctgov-nct07531108-2026-04-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07531108-2026-04-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effects of Empagliflozin-Metformin, Sitagliptin-Metformin, and Metformin on Adipokines in Type 2 Diabetes
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Empagliflozin-Metformin
- Intervention (Drug): Sitagliptin-Metformin
- Intervention (Drug): Metformin
- Lead sponsor: Hawler Medical University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: 5479bc763b346b17d827447e9e1fb3f11bbcb122d38b9ab865a2f24a32001969
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
